2 weeks Ago By ABMN Staff
Vanguard Group Inc. cut its stake in shares of Cerus Co. ( NASDAQ:CERS – Free Report ) by 4.
0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,416,038 shares of the biotechnology company’s stock after selling 432,060 shares during the quarter. Vanguard Group Inc.
owned 0.06% of Cerus worth $16,041,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Other institutional investors and hedge funds have also bought and sold shares of the company.
Rockport Wealth LLC purchased a new stake in shares of Cerus during the fourth quarter valued at approximately $25,000. Cibc World Markets Corp purchased a new position in shares of Cerus in the fourth quarter worth $26,000. R Squared Ltd bought a new stake in Cerus during the 4th quarter valued at $29,000.
Virtu Financial LLC purchased a new stake in Cerus during the 4th quarter valued at $33,000. Finally, PCA Investment Advisory Services Inc. bought a new stake in Cerus in the 4th quarter worth $46,000.
78.37% of the stock is currently owned by institutional investors. Analysts Set New Price Targets Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $4.
00 price objective on shares of Cerus in a research note on Friday, February 21st. Cerus Price Performance Shares of CERS stock opened at $1.30 on Friday.
The company has a debt-to-equity ratio of 1.19, a quick ratio of 1.92 and a current ratio of 2.
59. Cerus Co. has a fifty-two week low of $1.
12 and a fifty-two week high of $2.54. The firm has a market cap of $241.
53 million, a P/E ratio of -11.82 and a beta of 1.70.
The business’s 50 day moving average price is $1.50 and its 200-day moving average price is $1.66.
Cerus ( NASDAQ:CERS – Get Free Report ) last released its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.01) earnings per share for the quarter, meeting the consensus estimate of ($0.
01). The business had revenue of $50.81 million for the quarter, compared to analysts’ expectations of $50.
81 million. Cerus had a negative net margin of 11.60% and a negative return on equity of 40.
55%. On average, equities research analysts anticipate that Cerus Co. will post -0.
08 earnings per share for the current year. Insider Activity In other Cerus news, CFO Kevin Dennis Green sold 60,656 shares of the business’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $1.
58, for a total value of $95,836.48. Following the sale, the chief financial officer now directly owns 493,862 shares of the company’s stock, valued at approximately $780,301.
96. The trade was a 10.94 % decrease in their ownership of the stock.
The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link . Also, CEO William Mariner Greenman sold 23,023 shares of the firm’s stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $1.
55, for a total value of $35,685.65. Following the transaction, the chief executive officer now owns 3,230,000 shares of the company’s stock, valued at $5,006,500.
The trade was a 0.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here .
In the last 90 days, insiders have sold 441,150 shares of company stock valued at $665,210. Corporate insiders own 3.40% of the company’s stock.
Cerus Profile ( Free Report ) Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
See Also Want to see what other hedge funds are holding CERS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cerus Co. ( NASDAQ:CERS – Free Report ).
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter ..
